Aura Biosciences (AURA)
(Delayed Data from NSDQ)
$7.35 USD
0.00 (0.00%)
Updated May 31, 2024 04:00 PM ET
After-Market: $7.36 +0.01 (0.14%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AURA 7.35 0.00(0.00%)
Will AURA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AURA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AURA
Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet
Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade
AURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for AURA
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
Aura Energy Expands Quotation with New Options
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Collplant Holdings (CLGN) and Zimmer Biomet Holdings (ZBH)
Aura Energy Finalizes Share Issuance & Preps Resource Update
Aura Energy Expands Securities on ASX